Literature DB >> 2669193

Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor.

B C Sheppard1, D L Fraker, J A Norton.   

Abstract

Tumor necrosis factor (TNF) is a macrophage product released in response to endotoxin that has been implicated as a cause of the toxicity and lethality seen in septic shock. Previous work suggests that tolerance to nutritional and lethal effects of TNF occur after repeated exposure to recombinant tumor necrosis factor (rTNF). In this study pretreatment of rats with a single low intravenous dose of rTNF prevented subsequent death when a lethal dose of rTNF was administered 24 hours later (tolerance or tachyphylaxis). Pretreatment with rTNF also afforded protection against the lethal effects of either endotoxin or cecal ligation and puncture when rats were challenged 24 hours later. Recombinant TNF injected 6 hours after cecal ligation and puncture initially resulted in a significant survival advantage for treated animals. When this experiment was repeated with a different lot of rTNF, however, the therapeutic benefit of rTNF was not obtained until the dose was decreased by a factor of 10. Protection against the lethal effects of cecal ligation and puncture did not occur when rTNF was given 24 hours after the insult. A single low dose of rTNF can result in tolerance or tachyphylaxis to the lethal effects of TNF. The results suggest that the early administration of low-dose rTNF may be useful in the prevention and treatment of the lethality of sepsis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2669193

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

1.  Increased distribution and expression of CD64 on blood polymorphonuclear cells from patients with the systemic inflammatory response syndrome (SIRS).

Authors:  S S Qureshi; S M Lewis; V A Gant; D Treacher; B H Davis; K A Brown
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  TNF-alpha is a mediator of the anti-inflammatory response in a human neonatal model of the non-septic shock syndrome.

Authors:  S Hassett; P Moynagh; D Reen
Journal:  Pediatr Surg Int       Date:  2006-01       Impact factor: 1.827

Review 3.  Use of immune modulators in nonspecific therapy of bacterial infections.

Authors:  M T Vogels; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 4.  Secondary peritonitis: principles of diagnosis and intervention.

Authors:  James T Ross; Michael A Matthay; Hobart W Harris
Journal:  BMJ       Date:  2018-06-18

5.  Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury : possible connection to an interleukin-6-dependent pathway.

Authors:  U Heemann; A Szabo; P Hamar; V Müller; O Witzke; J Lutz; T Philipp
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

6.  IL-1beta and IL-6 in community-acquired pneumonia: bacteremic pneumococcal pneumonia versus Mycoplasma pneumoniae pneumonia.

Authors:  D Lieberman; S Livnat; F Schlaeffer; A Porath; S Horowitz; R Levy
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

Review 7.  Evaluation of TNF as antiviral, antibacterial and antiparasitic agent.

Authors:  G A Rook; J Taverne; J H Playfair
Journal:  Biotherapy       Date:  1991

8.  Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis.

Authors:  H R Alexander; B C Sheppard; J C Jensen; H N Langstein; C M Buresh; D Venzon; E C Walker; D L Fraker; M C Stovroff; J A Norton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

9.  Protective effect of an oestrogen against endotoxin-induced liver enzyme release.

Authors:  N J Carbarns; M L Neale; J M Stark
Journal:  Int J Exp Pathol       Date:  1993-06       Impact factor: 1.925

10.  Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats.

Authors:  H R Alexander; G M Doherty; M I Block; P J Kragel; J C Jensen; H N Langstein; E Walker; J A Norton
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.